CANCER TESTIS ANTIGENS IN CANCER IMMUNOTHERAPY
Low toxicity, oncospecificity, immunogenicity and relatively frequent expression of CT antigens in many types of cancer justify their use in cancer immunotherapy. This review presents the data on CTA use in new clinical approaches to the malignant process control, developed from the ideas of the ant...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2017-06-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/523 |
| _version_ | 1797875863351459840 |
|---|---|
| author | D. I. Vodolazhsky O. I. Kit Kh. A. Mogushkova A. A. Pushkin N. N. Timoshkina |
| author_facet | D. I. Vodolazhsky O. I. Kit Kh. A. Mogushkova A. A. Pushkin N. N. Timoshkina |
| author_sort | D. I. Vodolazhsky |
| collection | DOAJ |
| description | Low toxicity, oncospecificity, immunogenicity and relatively frequent expression of CT antigens in many types of cancer justify their use in cancer immunotherapy. This review presents the data on CTA use in new clinical approaches to the malignant process control, developed from the ideas of the anti-tumor immunity mechanisms. In particular, we highlight the results of application of immune checkpoint inhibitors, external correction of the immune response by vaccination with ex vivo generated dendritic cells, natural killer cells and T-lymphocytes; induction and synchronization of CTA expression with DNA hypomethylating agents to enhance the immunogenicity of cancer cells, etc. As a result, we demonstrate the need for rethinking current clinical strategies in terms of the choice of chemotherapeutic agents and immunotherapy design, which will significantly increase the effectiveness of cancer treatment. |
| first_indexed | 2024-04-10T01:53:19Z |
| format | Article |
| id | doaj.art-744258c8b48243a28f927ed101da4958 |
| institution | Directory Open Access Journal |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| last_indexed | 2024-04-10T01:53:19Z |
| publishDate | 2017-06-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj.art-744258c8b48243a28f927ed101da49582023-03-13T09:05:50ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682017-06-01162718110.21294/1814-4861-2017-16-2-71-81438CANCER TESTIS ANTIGENS IN CANCER IMMUNOTHERAPYD. I. Vodolazhsky0O. I. Kit1Kh. A. Mogushkova2A. A. Pushkin3N. N. Timoshkina4ФГБУ «Ростовский научно-исследовательский онкологический институт» Минздрава РоссииФГБУ «Ростовский научно-исследовательский онкологический институт» Минздрава РоссииФГБУ «Ростовский научно-исследовательский онкологический институт» Минздрава РоссииФГБУ «Ростовский научно-исследовательский онкологический институт» Минздрава РоссииФГБУ «Ростовский научно-исследовательский онкологический институт» Минздрава РоссииLow toxicity, oncospecificity, immunogenicity and relatively frequent expression of CT antigens in many types of cancer justify their use in cancer immunotherapy. This review presents the data on CTA use in new clinical approaches to the malignant process control, developed from the ideas of the anti-tumor immunity mechanisms. In particular, we highlight the results of application of immune checkpoint inhibitors, external correction of the immune response by vaccination with ex vivo generated dendritic cells, natural killer cells and T-lymphocytes; induction and synchronization of CTA expression with DNA hypomethylating agents to enhance the immunogenicity of cancer cells, etc. As a result, we demonstrate the need for rethinking current clinical strategies in terms of the choice of chemotherapeutic agents and immunotherapy design, which will significantly increase the effectiveness of cancer treatment.https://www.siboncoj.ru/jour/article/view/523раковый тестикулярный антигенканцерогенезиммунотерапия |
| spellingShingle | D. I. Vodolazhsky O. I. Kit Kh. A. Mogushkova A. A. Pushkin N. N. Timoshkina CANCER TESTIS ANTIGENS IN CANCER IMMUNOTHERAPY Сибирский онкологический журнал раковый тестикулярный антиген канцерогенез иммунотерапия |
| title | CANCER TESTIS ANTIGENS IN CANCER IMMUNOTHERAPY |
| title_full | CANCER TESTIS ANTIGENS IN CANCER IMMUNOTHERAPY |
| title_fullStr | CANCER TESTIS ANTIGENS IN CANCER IMMUNOTHERAPY |
| title_full_unstemmed | CANCER TESTIS ANTIGENS IN CANCER IMMUNOTHERAPY |
| title_short | CANCER TESTIS ANTIGENS IN CANCER IMMUNOTHERAPY |
| title_sort | cancer testis antigens in cancer immunotherapy |
| topic | раковый тестикулярный антиген канцерогенез иммунотерапия |
| url | https://www.siboncoj.ru/jour/article/view/523 |
| work_keys_str_mv | AT divodolazhsky cancertestisantigensincancerimmunotherapy AT oikit cancertestisantigensincancerimmunotherapy AT khamogushkova cancertestisantigensincancerimmunotherapy AT aapushkin cancertestisantigensincancerimmunotherapy AT nntimoshkina cancertestisantigensincancerimmunotherapy |